Established in 2018, CRC TRR 221 unites scientists and clinicians from the University of Regensburg, Friedrich-Alexander University Erlangen–Nuremberg, and Julius-Maximilians-University Würzburg. The network focuses on understanding and modulating immune responses following allogeneic stem cell transplantation—a life-saving procedure for patients with high-risk blood cancers and other hematologic diseases.

“Securing a third funding period is both a remarkable honor and a powerful recognition of the innovative work carried out within CRC TRR 221 over the past years,” said Dr. Wolfgang Herr, spokesperson and coordinator of the consortium.

“This achievement is a testament to the outstanding dedication and the distinctive collaborative spirit demonstrated by all scientists, physicians, students, partners, and supporting institutions involved. Their commitment and vision continue to push the boundaries of research and innovation.”

The research conducted within CRC TRR 221 aims to reduce the incidence and severity of graft-versus-host disease (GvHD)—a potentially life-threatening complication of stem cell transplantation—while enhancing the beneficial graft-versus-leukemia (GVL) response, which is essential for preventing disease relapse.

This renewed funding emphasizes not only the scientific excellence but also the effective interdisciplinary and inter-institutional collaboration that characterizes the CRC TRR 221 network. Through a combination of basic, translational, and clinical research approaches, the consortium has made important contributions to understanding the immune mechanisms that govern post-transplant complications and outcomes.

With this new phase of funding, the CRC 221 team is well-positioned to further accelerate discoveries, develop novel therapeutic strategies, and ultimately improve long-term outcomes for transplant recipients.

“We are excited to continue our work and deepen our understanding of these critical immunological processes,” added/adds Dr. Herr. “The support from the DFG allows us to build on a strong foundation and take meaningful steps toward translating our findings into better patient care.